A Novartis treatment for early-stage breast cancer has been shown to reduce the risk of recurrence by 25 percent. This treatment, ribociclib, is developed by Novarts against the most common type of breast cancer.
The drug is already used (in combination with hormone therapy) for patients with advanced cancer with metastases. "This is a very important clinical trial and one that will change the practice" of doctors, says Rita Nanda, an oncologist at the University of Chicago.